杨PT -期刊文章盟夏盟——黄,秀AU -金,瑞盟-李,沈盟——温家宝Huahao TI -的功效Ado-trastuzumab emtansine her - 2异常的非小细胞肺癌援助- 10.1183/13993003.国会- 2019。PA4669 DP - 2019年9月28日TA -欧洲呼吸杂志PG - PA4669 VI - 54 IP - 63 4099 - //www.qdcxjkg.com/content/54/suppl_63/PA4669.short 4100 - //www.qdcxjkg.com/content/54/suppl_63/PA4669.full -欧元和J2019 9月28日;54 AB的疗效ado-trastuzumab emtansine HER-2-altered肺癌患者不同。因此,我们评估的有效性T-DM1治疗不同亚型的her - 2畸变。我们寻找发表文章、案例报告,和正在进行的研究报告的有效性T-DM1肺癌her - 2畸变。七个研究符合系统评价的标准。这些研究的主要结果是整体回应率(ORR)。九十三例各种her - 2畸变被确定在7个研究。超表达her - 2 upregulation(蛋白质和/或基因扩增)更常见的吸烟史和腺癌患者,在没有与性有关的差异,而her - 2基因突变与腺癌更常见于女性非吸烟者。奥尔的her - 2畸变是19.35%。 Subgroup analyses showed an ORR of 35.00% for HER-2 mutation, 42.86% for HER-2 gene amplification, and 2.78% for HER-2 protein overexpression. Notably, the ORR was only 8.33% for HER-2 upregulation but was significantly increased to 46.15% upon concomitant HER-2 upregulation and mutation. Furthermore, the ORR was 25.00% for overexpression plus mutation but up to 80.00% for gene amplification plus overexpression and mutation. T-DM1 is a promising agent targeting HER-2 mutations or amplification in lung cancers, and the therapeutic efficacy may be better for cancers with HER-2 mutation plus amplification. Additional studies of this agent are warranted to confirm the tentative conclusions of this analysis.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4669.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).